Rhythm Biosciences (ASX:RHY) completed the initial integration of the Genetype business it acquired on Dec. 24, 2024, with the commercial processes required to provide and sell the geneType genetic risk assessment product restored, according to a Tuesday Australian bourse filing.
The integration was expected to take over 12 weeks earlier. Full integration is now expected to be completed by the end of February, per the filing.
The firm said the transition included the transfer, restoration, and rebuilding of several processes and supply partnerships.
The firm's shares fell past 2% in recent trading on Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.